Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SAFX | 8-K, S-4/A | neutral | 5/10 | XCF Global filed a preliminary proxy statement and an amended S-4 registration statement on July 27, 2026, setting a spe | Jul 27, 2026 |
| AZN | 6-K | mixed | 5/10 | AstraZeneca reported Phase III results for Ultomiris in HSCT-TMA: the adult/adolescent trial (ALXN1210-TMA-313) failed t | Jul 27, 2026 |
| MPLT | 8-K | bullish | 7/10 | MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia. T | Jul 27, 2026 |
| SAFX | DEFA14A | bearish | 6/10 | XCF Global filed a definitive proxy statement (DEFA14A) soliciting shareholder approval for a business combination with | Jul 27, 2026 |
| NMRA | 8-K | bullish | 5/10 | Neumora Therapeutics reported favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhib | Jul 27, 2026 |
| DTIL | 8-K | neutral | 3/10 | Precision BioSciences announced a senior leadership reshuffle effective August 1, 2026: CFO Alex Kelly promoted to the n | Jul 27, 2026 |
| AZN | 6-K | mixed | 6/10 | AstraZeneca reported H1 2026 Total Revenue of $30.7B (+6% CER) and Core EPS of $5.21 (+11% CER), with strong double-digi | Jul 27, 2026 |
| IMRN | 6-K | neutral | 4/10 | Immuron Ltd filed a 6-K with an investor presentation highlighting FY26 global sales revenue of A$7.7 million (up 6% YoY | Jul 27, 2026 |
| VREOF | 8-K | neutral | 5/10 | Vireo Growth Inc. announced a definitive merger agreement to acquire Planet 13 Holdings Inc., adding 36 dispensaries and | Jul 27, 2026 |
| SRPT | 8-K | neutral | 3/10 | Sarepta Therapeutics appointed Michael Severino, M.D., as CEO effective July 28, 2026, succeeding Doug Ingram who is ret | Jul 27, 2026 |
| PRFX | 6-K | mixed | 5/10 | PRF Technologies issued a shareholder letter highlighting a $10 million capital raise from its equity line facility, whi | Jul 27, 2026 |
| JUNS | 8-K | bearish | 6/10 | Jupiter Neurosciences held its 2026 annual meeting, approving a reverse stock split (1:10 to 1:100, board discretion) an | Jul 27, 2026 |
| DBVT | S-3ASR | bearish | 6/10 | DBV Technologies filed an automatic shelf registration statement (S-3ASR) to offer up to $150 million in ADSs via an at- | Jul 27, 2026 |
| KYTX | 8-K | neutral | 4/10 | Kyverna Therapeutics entered into a 5-year Clinical and Commercial Supply Agreement with ElevateBio for its lead CAR T-c | Jul 27, 2026 |
| NNVC | 424B5 | bearish | 6/10 | NanoViricides is raising approximately $3.5M in net proceeds via a registered direct offering of 2,416,339 shares of com | Jul 27, 2026 |
| HROW | PRESS-RELEASE | neutral | 1/10 | Harrow, Inc. announced it will report its Q2 2026 results on August 10, 2026. | Jul 27, 2026 |
| TNXP | PRESS-RELEASE | neutral | 1/10 | Tonix Pharmaceuticals Holding Corp. announced it will report its Q2 2026 results on August 10, 2026. | Jul 27, 2026 |
| NMRA | PRESS-RELEASE | bullish | 7/10 | Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhi | Jul 27, 2026 |
| FBRX | 8-K | bullish | 8/10 | Forte Biosciences (FBRX) has entered into a definitive merger agreement to be acquired by argenx (ARGX) for $77.00 per s | Jul 27, 2026 |
| ARGX | 6-K | bullish | 7/10 | argenx announced a definitive agreement to acquire Forte Biosciences for $77 per share in cash, a total equity value of | Jul 27, 2026 |
| NNVC | 424B5 | neutral | 4/10 | NanoViricides filed an amendment to its prospectus supplement that effectively pauses its at-the-market (ATM) offering p | Jul 27, 2026 |
| JAGX | EFFECT | bearish | 8/10 | Two S-1 registration statements for Jaguar Health (JAGX) became effective on July 24, 2026, covering File Nos. 333-29748 | Jul 27, 2026 |
| VRXA | 6-K | neutral | 4/10 | Veraxa Biotech AG filed a comprehensive Form 6-K consolidating multiple July 2026 events: shareholders approved amendmen | Jul 27, 2026 |
| LEGN | 6-K | bearish | 6/10 | Legend Biotech CEO Ying Huang resigned effective July 24, 2026, with no disagreement cited. The Board appointed Alan Bas | Jul 27, 2026 |
| LEEEF | EFFECT | neutral | 3/10 | Leef Brands Inc. received SEC effectiveness on July 24, 2026 for its S-1 registration statement (File No. 333-297329), e | Jul 27, 2026 |
| RADX | 424B5 | bearish | 6/10 | Radiopharm Theranostics is raising approximately $4.05M in gross proceeds through a registered direct offering of 1,281, | Jul 27, 2026 |
| CYCN | EFFECT | mixed | 7/10 | Cyclerion Therapeutics' S-4 registration statement (File No. 333-295175) was declared effective by the SEC on July 24, 2 | Jul 27, 2026 |
| SCTX | 424B4 | neutral | 6/10 | Scribe Therapeutics priced its IPO at $15.00 per share, offering 8,580,000 shares for total gross proceeds of $128.7 mil | Jul 27, 2026 |
| LEGN | PRESS-RELEASE | neutral | 4/10 | Legend Biotech CEO Ying Huang stepped down effective July 24, 2026; Alan Bash, President of the CARVYKTI Business Unit, | Jul 27, 2026 |
| ARGX | PRESS-RELEASE | bullish | 7/10 | argenx is acquiring Forte Biosciences for $77/share in cash, total equity value ~$2.2B, an 86% premium to Forte's VWAP s | Jul 27, 2026 |